p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus

Modern Pathology

Volumn 14, Issue 5, 2001, Pages 397-403

  Bian, Yan Song ^a   Osterheld, Maria Chiara ^a   Bosman, Fred T ^a   Benhattar, Jean ^a   Fontolliet, Charlotte ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Barrett's esophagus; Immunohisto chemistry; p53; Single strand conformation polymorphism

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER SURVIVAL; CLINICAL ARTICLE; DYSPLASIA; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035031816     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880324     Document Type: Article

References (44)

1. Phillips RW, Wong RKH. Barrett's esophagus. Natural history, incidence, etiology and complications. Gastroenterol Clin North Am 1991;20:791-816.
2. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994;344:1533-6.
3. Van der Veen AH, Dees J, Blankenstein JD, Van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989;30:14-8.
4. Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, et al. Adenocarcinoma and Barrett's esophagus: an overrated risk? Gastroenterology 1984;84:927-33.
5. Spechler SJ. The columnar-lined esophagus. History, terminology and clinical issues. Gastroenterol Clin North Am 1977;26:455-66.
6. Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
7. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-19.
8. Rabinovitch PS, Reid BJ, Haggitt RC, Norwood TH, Rubin CE. Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest 1988;60:65-71.
9. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
10. Levine AJ. The p53 tumor-suppressor gene. N Engl J Med 1992;326:1350-52.
11. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 gene mutation in Barrett's epithelium and esophageal cancer. Cancer Res 1991;51:4495-9.
12. Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu SM, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992;52:6092-7.
13. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, et al. p53 mutation in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-95.
14. Schneider PM, Casson AG, Levin B, Garewal HS, Hoelscher AH, Becker K, et al. Mutation of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 1996;111:323-33.
15. Wang LD, Hong JY, Qiu SL, Gao H, Yang CS. Accumulation of p53 protein in human esophageal precancerous lesions: a possible early marker for carcinogenesis. Cancer Res 1993; 53:1783-7.
16. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Russell SE. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 1995; 55:3406-11.
17. Ramel S, Reid BJ, Sanchez CA, Blount PL, Levine DS, Neshat K, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992;102:1220-8.
18. Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F, et al. TP53 gene mutation and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994;107:1012-8.
19. Krishnadath KK, Tilanus HW, Blankenstein MV, Bosman FT, Mulder AH. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J Pathol 1995;175: 175-80.
20. Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin J, Ozcelik H. p53 alteration in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol 1998;51:71-9.
21. Casson AG, Manolopoulos B, Troster M, Kerkvliet N, O'Malley F, Inculet R, et al. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Am J Surg 1994;167:52-7.
22. Ireland AP, Clark GWB, Demeester TR. Barrett's esophagus: the significance of p53 in clinical practice. Ann Surg 1997; 225:17-30.
23. Kubba AK, Pool NA, Watson A. Role of p53 assessment in management of Barrett's esophagus. Dig Dis Sci 1999;44: 659-67.
24. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? J Pathol 1994;172:1-4.
25. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms a hsc700-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
26. Robbins BDP, Carrello S, House A, Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 1994;70:585-90.
27. Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S, Hirohashi S. High incidence of p53 mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992; 83:978-84.
28. Melhem MF, Law JC, El-Ashmawy L, Johnson JT, Landreneau RJ, Srivastava S, et al. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 1995;146:1170-7.
29. Mori M, Adachi Y, Kakeji Y, Korenaga D, Sugimachi K, Motooka M, et al. Superficial flat-type early carcinoma of the stomach. Cancer 1992;69:306-13.
30. Haggitt RC. Histopathology of reflux-induced esophageal and supraesophageal injuries. Am J Med 2000;108:109S-11S.
31. Baisse B, Bian YS, Benhattar J. Microdissection by exclusion and DNA extraction for multiple PCR analyses from archival tissue sections. Biotechniques 2000;28:856-62.
32. Chaubert P, Bautista D, Benhattar J. An improved method for rapid screening of DNA mutations by non-radioactive single-strand conformation polymorphism procedure. Biotechniques 1993;15:586.
33. Hurlimann J, Chaubert P, Benhattar J. p53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol 1994;7:423-8.
34. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-51.
35. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-27.
36. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor DNA-complex: understanding tumorigenic mutations. Science 1994;265:346-55.
37. Wagata T, Shibagaki I, Imamura M, Shimada Y, Toguchida J, Yandell DW, et al. Loss of 17p, mutation of p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinoma. Cancer Res 1993;53:846-50.
38. Shi ST, Yang GY, Wang LD, Xue ZH, Feng B, Ding W, et al. Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenesis 1999;20:591-7.
39. Lohmann D, Putz B, Reich U, Bohm J, Prauer H, Hofler H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relation to clinicopathological data. Am J Pathol 1993;142:907-15.
40. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
41. Zambetti GP, Levine AJ. A comparison of biological activities of wild-type and mutant p53. FASEB J 1993;7: 855-65.
42. Khan S, Do KA, Kuhnert P, Pillay SP, Papadimos D, Conrad R, et al. Diagnostic value of p53 immunohistochemistry in Barrett's esophagus: an endoscopic study. Pathology 1998; 30:136-40.
43. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 1995;221:677-84.
44. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. Cancer 1997;79:425-32.